Mediastinal (thymic) large B-cell lymphoma: where do we stand?
- PMID: 12067685
- DOI: 10.1016/s1470-2045(02)00714-3
Mediastinal (thymic) large B-cell lymphoma: where do we stand?
Abstract
Mediastinal (thymic) B-cell lymphoma (MBL) is a locally highly aggressive tumour that was first definitively described in the early 1980s. The incidence of MBL is low, which made disease characterisation difficult initially. However, MBL has several peculiar clinical, morphological, immunological, and genetic features. Collectively, these characteristics distinguish it from other diffuse, large B-cell lymphomas. Consequently, MBL has become a defined subtype of diffuse large B-cell lymphoma with its own code (9679/3) in the International Classification of Diseases. New insights into the biological and clinical aspects of MBL have been gained from the study of large numbers of cases. Nevertheless, the histogenesis of the disease is not yet fully understood. We review the available data on MBL with special emphasis on its morphological, immunological, and genetic properties. Also discussed are recent data on molecular genetics, biology, and treatment.
Similar articles
-
[Mediastinal large B-cell lymphoma].Pathologe. 2007 Feb;28(1):36-40. doi: 10.1007/s00292-006-0880-8. Pathologe. 2007. PMID: 17195039 German.
-
Mutational analysis of IgVH and BCL-6 genes suggests thymic B-cells origin of mediastinal (thymic) B-cell lymphoma.Leuk Lymphoma. 2004 Oct;45(10):2105-10. doi: 10.1080/1042819042000219467. Leuk Lymphoma. 2004. PMID: 15370257
-
Primary mediastinal large B-cell lymphoma.Oncologist. 2006 May;11(5):488-95. doi: 10.1634/theoncologist.11-5-488. Oncologist. 2006. PMID: 16720849 Review.
-
Diffuse large B-cell lymphoma and its variants.Croat Med J. 2002 Oct;43(5):535-40. Croat Med J. 2002. PMID: 12402391
-
Mediastinal B-cell lymphoma, a lymphoma type with several characteristics unique among diffuse large B-cell lymphomas.Ann Hematol. 2001;80 Suppl 3:B49-53. doi: 10.1007/pl00022789. Ann Hematol. 2001. PMID: 11757707 Review.
Cited by
-
Gray zone lymphoma effectively treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab chemotherapy: A case report.World J Clin Cases. 2022 Jun 16;10(17):5708-5716. doi: 10.12998/wjcc.v10.i17.5708. World J Clin Cases. 2022. PMID: 35979119 Free PMC article.
-
Double-punching PMBL.Oncotarget. 2014 Nov 30;5(22):10965-6. doi: 10.18632/oncotarget.2827. Oncotarget. 2014. PMID: 25473898 Free PMC article. No abstract available.
-
The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification.Cancer J. 2012 Sep-Oct;18(5):411-20. doi: 10.1097/PPO.0b013e31826aee97. Cancer J. 2012. PMID: 23006945 Free PMC article. Review.
-
Successful Management of Primary Mediastinal Large B-cell Lymphoma during Pregnancy.Intern Med. 2019 Dec 1;58(23):3455-3459. doi: 10.2169/internalmedicine.3129-19. Epub 2019 Aug 6. Intern Med. 2019. PMID: 31391392 Free PMC article.
-
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.Haematologica. 2021 Jun 1;106(6):1705-1713. doi: 10.3324/haematol.2019.238675. Haematologica. 2021. PMID: 32414850 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous